Compare Novartis AG (NVS) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Veritone Inc — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Veritone Inc trades at $0.61 (market cap $59.46M). The key difference: Novartis AG is far larger — about 4516.8× Veritone Inc's market cap, and Novartis AG pays a 3.31% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Veritone Inc for 12 Days on average.
| NVS | VERI | |
|---|---|---|
Market Cap | $268.57B | $59.46M |
Volume | 1,532,573 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $168.62 | $8.39 |
52-Week Low | $121.80 | $0.59 |
Typical Hold Time | 82 Days | 12 Days |
Enterprise Value | $309.89B | $94.86M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Veritone (VERI) trades at $0.69, down 7.38% over 24 hours, reflecting ongoing investor concerns. The stock is technically bearish with negative earnings trends, including a net income margin of -117.54% for 2025. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are overshadowed by a securities class action investigation and consistent quarterly losses.
The outlook remains challenging due to persistent unprofitability and high cash burn. The consensus price target of $3.75 offers significant upside if the company can achieve cost reductions and revenue growth, but execution risks and legal overhangs present substantial headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
